+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Non-Rhabdomyosarcoma Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768120
  • Report
  • April 2019
  • Region: Global
  • 198 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
The global clinical trial report- “2019 Non-Rhabdomyosarcoma Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Non-Rhabdomyosarcoma. It presents in-depth analysis of Non-Rhabdomyosarcoma clinical trials across markets and companies. The research work is for providing complete understanding into trends in Non-Rhabdomyosarcoma.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Non-Rhabdomyosarcoma clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Non-Rhabdomyosarcoma

The research work is prepared through extensive and continuous research on Non-Rhabdomyosarcoma trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Non-Rhabdomyosarcoma patients are identified
  • The report includes panorama of Non-Rhabdomyosarcoma clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Non-Rhabdomyosarcoma clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Non-Rhabdomyosarcoma Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Non-Rhabdomyosarcoma Clinical Trials by Region
2.2.2 Average Enrollment of Non-Rhabdomyosarcoma Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Non-Rhabdomyosarcoma Treatment, 2019

3. Region wise Non-Rhabdomyosarcoma Clinical Trials
3.1 Asia Pacific Non-Rhabdomyosarcoma Clinical Trials by Country
3.2 Europe Non-Rhabdomyosarcoma Clinical Trials by Country
3.3 North America Non-Rhabdomyosarcoma Clinical Trials by Country
3.4 Middle East and Africa Non-Rhabdomyosarcoma Clinical Trials by Country
3.5 South and Central America Non-Rhabdomyosarcoma Clinical Trials by Country

4. Non-Rhabdomyosarcoma Clinical Trial Trends
4.1 Start Year wise Non-Rhabdomyosarcoma Clinical Trials
4.2 Phase wise Non-Rhabdomyosarcoma Clinical Trials
4.3 Trial Status wise Non-Rhabdomyosarcoma Clinical Trials
4.4 Trial Type wise Non-Rhabdomyosarcoma Clinical Trials

5. Non-Rhabdomyosarcoma Average Enrollment Trends
5.1 Average Enrollment in Non-Rhabdomyosarcoma Trials by Year
5.2 Average Enrollment in Non-Rhabdomyosarcoma Trials by Phase
5.3 Average Enrollment in Non-Rhabdomyosarcoma Trials by Status
5.4 Average Enrollment in Non-Rhabdomyosarcoma Trials by Type of Trial

6. Companies Participating in Non-Rhabdomyosarcoma Clinical Trials
6.1 Non-Rhabdomyosarcoma Trials by Sponsor Type
6.2 Non-Rhabdomyosarcoma Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Non-Rhabdomyosarcoma Trials- Phase 1
7.2 Non-Rhabdomyosarcoma Trials- Phase 2
7.3 Non-Rhabdomyosarcoma Trials- Phase 3
7.4 Non-Rhabdomyosarcoma Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Non-Rhabdomyosarcoma Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Figure 5: Europe - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Figure 7: North America - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Figure 9: Non-Rhabdomyosarcoma Clinical Trials by Phase
Figure 10: Non-Rhabdomyosarcoma Clinical Trials by Trial Status
Figure 11: Non-Rhabdomyosarcoma Clinical Trials by Type
Figure 12: Non-Rhabdomyosarcoma Clinical Trials by Sponsor Type
Figure 13: Non-Rhabdomyosarcoma Clinical Trials by Leading Sponsors
Figure 14: Non-Rhabdomyosarcoma Average Enrollment by Phase
Figure 15: Non-Rhabdomyosarcoma Average Enrollment by Trial Status
Figure 16: Non-Rhabdomyosarcoma Average Enrollment by Type
Figure 17: Non-Rhabdomyosarcoma- Average Enrolment by Type of Sponsors
Figure 18: Non-Rhabdomyosarcoma- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Non-Rhabdomyosarcoma Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Table 5: Europe - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Table 7: North America - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Non-Rhabdomyosarcoma Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Non-Rhabdomyosarcoma Average Enrollment by Phase
Table 15: Non-Rhabdomyosarcoma Average Enrollment by Trial Status
Table 16: Non-Rhabdomyosarcoma Average Enrollment by Type
Table 17: Non-Rhabdomyosarcoma- Average Enrolment by Type of Sponsors
Table 18: Non-Rhabdomyosarcoma- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Pharma Mar SA
Note: Product cover images may vary from those shown
Adroll
adroll